While the precise mechanisms remain unclear, psychedelics like psilocybin are believed to alter brain communication pathways, similar to antidepressants, which may explain their mental health benefits.

Participants experienced rapid mental health improvements within 24 hours, with some reporting lasting benefits for up to six months, including better mood, outlook, and a sense of connection.

Many reported significant reductions in depression and anxiety, with some describing spiritually meaningful experiences that helped them come to peace with their prognosis.

Clinicians emphasize that while the results are promising, psychedelic-assisted therapy is still in early stages and not suitable for all patients.

One participant, Michael Quinn, shared that the treatment helped him accept his prognosis, even if he did not enjoy the psychedelic experience itself.

A pioneering Australian clinical trial at St Vincent's Hospital Melbourne explored the use of psilocybin, a compound found in magic mushrooms, combined with psychotherapy to treat depression and anxiety in terminally ill patients.

The study involved 35 patients with advanced illnesses like cancer and motor neurone disease, who received two doses of psilocybin during eight-hour sessions, along with pre- and post-treatment psychotherapy.

Conducted over nearly three years, the trial aimed to assess how psilocybin, when combined with therapy, could alleviate severe anxiety, depression, and distress about death among terminally ill individuals.

Australian psychiatrist Eli Kotler highlighted the importance of cautious use of psychedelics, emphasizing their potential to alleviate human suffering and the need for healing-focused approaches.

Patients receiving psilocybin saw their depression severity drop below diagnostic levels, whereas the placebo group experienced only minor improvements.

Participants also underwent psychotherapy sessions before and after dosing to help process their experiences.

Access to psychedelic-assisted therapy remains limited and costly, with some clinics charging over $27,000, though there are hopes for insurance coverage and group sessions to reduce costs.

The therapy involved two sessions—one with psilocybin or placebo, and a second with psilocybin for all—conducted in a quiet, sensory-controlled environment with curated music and clinician monitoring.